JuanJuan Yin

JuanJuan Yin

Auto-generated profile, based on publicly available information

JuanJuan Yin

National Cancer Institute 5 Genitourinary Malignancies Branch Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
LLLechen Li
Lechen Li
AAAmir H. Ameri
Amir H. Ameri
SWSimeng Wang
Simeng Wang
KJKeith H. Jansson
Keith H. Jansson
OCOrla M. Casey
Orla M. Casey
KKKathleen Kelly
Kathleen Kelly

1 June 2015 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
YLYen-Nien Liu
Yen-Nien Liu
JYJuanJuan Yin
JuanJuan Yin
BBBen Barrett
Ben Barrett
HSHeather Sheppard-Tillman
Heather Sheppard-Tillman
DLDongmei Li
Dongmei Li
KKKathleen Kelly
Kathleen Kelly
Bone metastasis is the hallmark of progressive and castration resistant prostate cancers. miR-1 levels are decreased in clinical samples of primary prostate cancer and further reduced in metastases. SRC has been implicated as a critical factor in bone metastasis, and here we show that SRC is a direct target of miR-1. In prostate cancer patient samples, miR-1 levels are inversely correlated with SRC expression and a SRC dependent gene signature. Ectopic miR-1 expression inhibited ERK signaling and bone metastasis in a xenograft model. In contrast, SRC overexpression was sufficient to reconstitute bone metastasis and ERK signaling in cells expressing high levels of miR-1. AR activity, defined by an AR output signature, is low in a portion of castration resistant prostate cancer. We show that AR binds to the miR-1-2 regulatory region, and regulates miR-1 transcription. Patients with low miR-1 levels displayed correlated low canonical AR gene signatures. Our data support the existence of an AR, miR-1, SRC regulatory network. We propose that loss of miR-1 is one mechanistic link between low canonical AR output and SRC promoted metastatic phenotypes.

15 November 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
supreet agarwalsupreet agarwal
supreet agarwal
LFLei Fang
Lei Fang
KMKerry McGowen
Kerry McGowen
JYJuanJuan Yin
JuanJuan Yin
JBJoel Bowman
Joel Bowman
KKKathleen Kelly
Kathleen Kelly
Antibody-drug conjugates (ADCs) are a promising targeted cancer therapy; however, patient selection based solely on target antigen expression without consideration for cytotoxic payload vulnerabilities has plateaued clinical benefits. Biomarkers to capture patients who might benefit from specific ADCs have not been systematically determined for any cancer. We present a comprehensive therapeutic and biomarker analysis of a B7H3-ADC with pyrrolobenzodiazepine(PBD) payload in 26 treatment-resistant, metastatic prostate cancer (mPC) models. B7H3 is a tumor-specific surface protein widely expressed in mPC, and PBD is a DNA cross–linking agent. B7H3 expression was necessary but not sufficient for B7H3-PBD-ADC responsiveness. RB1 deficiency and/or replication stress, characteristics of poor prognosis, and conferred sensitivity were associated with complete tumor regression in both neuroendocrine (NEPC) and androgen receptor positive (ARPC) prostate cancer models, even with low B7H3 levels. Non-ARPC models, which are currently lacking efficacious treatment, demonstrated the highest replication stress and were most sensitive to treatment. In RB1 WT ARPC tumors, SLFN11 expression or select DNA repair mutations in SLFN11 nonexpressors governed response. Importantly, WT TP53 predicted nonresponsiveness (7 of 8 models). Overall, biomarker-focused selection of models led to high efficacy of in vivo treatment. These data enable a paradigm shift to biomarker-driven trial designs for maximizing clinical benefit of ADC therapies.

2 July 2008 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MOMichael D Oberst
Michael D Oberst
SBStacey J Beberman
Stacey J Beberman
LZLiu Zhao
Liu Zhao
JYJuan Juan Yin
Juan Juan Yin
YWYvona Ward
Yvona Ward
KKKathleen Kelly
Kathleen Kelly
Introduction: Signaling downstream of Ras is mediated by three major pathways, Raf/ERK, phosphatidylinositol 3 kinase (PI3K), and Ral guanine nucleotide exchange factor (RalGEF). Ras signal transduction pathways play an important role in breast cancer progression, as evidenced by the frequent over-expression of the Ras-activating epidermal growth factor receptors EGFR and ErbB2. Here we investigated which signal transduction pathways downstream of Ras contribute to EGFR-dependent transformation of telomerase-immortalized mammary epithelial cells HME16C. Furthermore, we examined whether a highly transcriptionally regulated ERK pathway target, PHLDA1 (TDAG51), suggested to be a tumor suppressor in breast cancer and melanoma, might modulate the transformation process. Methods: Cellular transformation of human mammary epithelial cells by downstream Ras signal transduction pathways was examined using anchorage-independent growth assays in the presence and absence of EGFR inhibition. TDAG51 protein expression was down-regulated by interfering small hairpin RNA (shRNA), and the effects on cell proliferation and death were examined in Ras pathway-transformed breast epithelial cells. Results: Activation of both the ERK and PI3K signaling pathways was sufficient to induce cellular transformation, which was accompanied by up-regulation of EGFR ligands, suggesting autocrine EGFR stimulation during the transformation process. Only activation of the ERK pathway was sufficient to transform cells in the presence of EGFR inhibition and was sufficient for tumorigenesis in xenografts. Up-regulation of the PHLDA1 gene product, TDAG51, was found to correlate with persistent ERK activation and anchorage-independent growth in the absence or presence of EGFR inhibition. Knockdown of this putative breast cancer tumor-suppressor gene resulted in increased ERK pathway activation and enhanced matrix-detached cellular proliferation of Ras/Raf transformed cells. Conclusion: Our results suggest that multiple Ras signal transduction pathways contribute to mammary epithelial cell transformation, but that the ERK signaling pathway may be a crucial component downstream of EGFR activation during tumorigenesis. Furthermore, persistent activation of ERK signaling up-regulates TDAG51. This event serves as a negative regulator of both Erk activation as well as matrix-detached cellular proliferation and suggests that TDAG51 opposes ERK-mediated transformation in breast epithelial cells.

7 April 2022 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
LFLei Fang
Lei Fang
DLDongmei Li
Dongmei Li
JYJuanJuan Yin
JuanJuan Yin
HPHong Pan
Hong Pan
HYHuihui Ye
Huihui Ye
KKKathleen Kelly
Kathleen Kelly

1 August 2025 in Cancer Research Communications
Verified
Journal Article
Open access
BBBenjamin C. Brim
Benjamin C. Brim
ALAndres F. Leon
Andres F. Leon
EBErica L. Beatson
Erica L. Beatson
JKJessica D. Kindrick
Jessica D. Kindrick
KBKinjal Bhadresha
Kinjal Bhadresha
William FiggWilliam Figg
William Figg
There is an unmet need to develop novel treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). Patients often develop resistance to next-generation hormonal therapies that target the androgen receptor (AR) axis (e.g., abiraterone and enzalutamide). A splice variant of AR, AR-V7, is associated with resistance to these inhibitors as well as mCRPC progression and poor prognoses. We embarked upon a high-throughput screen to identify synergistic combinations of targeted therapies using two CRPC cell lines, LNCaP95 and VCaP-CR. Combinations targeting BCL2L1 (Bcl-xL) (A-1331852 and navitoclax) and MCL1 (S63845) synergistically decreased cell viability and induced apoptotic activity via cleavage of PARP, caspase 3, and caspase 7 across AR-V7–expressing CRPC cell lines (LNCaP95, VCaP-CR, and 22Rv1) and a patient-derived organoid model (LuCaP 167CR). We also explored the use of a Bcl-xL–specific proteolysis-targeting chimera degrader (PROTAC) to minimize platelet toxicity associated with Bcl-xL inhibitors. We showed similar synergistic efficacy with the Bcl-xL–targeting PROTAC in combination with S63845 in the three-dimensional spheroid models. Our findings support further preclinical development of Bcl-xL and Mcl-1 inhibitors for mCRPC. Significance: Using an unbiased, combinatorial, high-throughput drug screen, we identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across AR-V7–expressing CRPC models. We showed efficacy in higher-order models through validation across in vitro models spanning two-dimensional cell culture, three-dimensional cell culture, and a patient-derived organoid model. These findings identify a promising therapeutic strategy for patients with AR-V7–expressing CRPC.